A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
|Articles|August 3, 2010
Come Down to Their Level
When dealing with children, I always try to sit so that I am at eye level with them.
Advertisement
When dealing with children, I always try to sit so that I am at eye level with them, I praise them for being brave and smart, and I make a point of being friendly to both them and their parents. Most important, I keep plenty of stickers on hand to give out.
--
Benjamin Barankin, MD
Toronto
Advertisement
Related to this article
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.
Advertisement
Advertisement
Trending on Patient Care Online
1
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
2
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
3
Clinical Inertia and Poor Measurement Technique Undermine BP Control
4
FAQ: What the Endocrine Society’s New Scientific Statement Means for Obesity Treatment
5